Rencontrez-nous à…

Toute l’actualité d’OTR3

  • Apr, 2023 – Publication

    News

    OTR3 is proud to share a recent publication in the “Aesthetic Surgery Journal Open Forum” from the Oxford University Press concerning “a retrospective self-controlled study evaluating the Prophylactic Effects of our Medical Device Cacipliq 20 on Postsurgical scars.” https://doi.org/10.1093/asjof/ojad031 Aesthetic Surgery Journal Open Forum (ASJOF) is an international award-winning, peer-reviewed, [...]

  • Dec, 2022 – Clinical

    News

    OTR3 announces first patient enrollment in its pivotal study “MATRISCAR”, a double blind placebo-controlled study aimed at demonstrating the effects of CACIPLIQ20 on Post-surgical Scars

  • Feb 10, 2022 – Clinical

    News

    OTR3 announces first patient enrolled in a post market clinical follow up on Cacipliq 20®..

  • Nov 9, 2021 – Clinical

    News

    OTR3 starts a post market clinical follow up on Cacipliq 20®.

  • Oct 8, 2021 – Clinical

    News

    OTR3 receives approval from ANSM to start new clinical trial with the application of a RGTA® product in ischemic stroke.

  • Aug 25, 2021 – Financial

    News

    OTR3 receives a state guaranteed loan amounting to € 0.5 m.

  • Jun 29, 2021 – Corporate

    News

    OTR3 appoints new management teams as the company planned to launch a second generation of RGTA® products.

  • Cacipliq 20® – Ischemic wound

    Cacipliq 20

    Cacipliq 20® - Ischemic wound First Clinical Pilot Study on critical ischemic leg ulcers with Matrix Therapy ReGeneraTing Agent (RGTA ® ) technology P. DESGRANGES, T. LOUISSAINT, E. ALLAIRE, B. GODEAU, K. KICHENIN, J.- P. BECQUEMIN, D. BARRITAULT Patients with non-healing leg ulcers due to severe limb ischemia and [...]